Amedisys Stock Performance
| AMED Stock | USD 90.64 0.48 0.53% |
The firm shows a Beta (market volatility) of 0.27, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Amedisys' returns are expected to increase less than the market. However, during the bear market, the loss of holding Amedisys is expected to be smaller as well. At this point, Amedisys has a negative expected return of -0.12%. Please make sure to confirm Amedisys' potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if Amedisys performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Amedisys has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's technical and fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.81 | Five Day Return 1.79 | Year To Date Return (3.79) | Ten Year Return 250.08 | All Time Return 1.6 K |
Last Split Factor 4:3 | Last Split Date 2006-12-05 |
1 | 3 Reasons UnitedHealth Group Is One of the Best Dividend Stocks You Can Own | 09/06/2024 |
2 | Will Amedisys Beat Estimates Again in Its Next Earnings Report | 10/16/2024 |
3 | UnitedHealth to Make Last Push for DOJ Blessing on Amedisys Deal | 10/25/2024 |
4 | Short Interest in Amedisys, Inc. Drops By 8.4 | 10/31/2024 |
5 | Acquisition by Nick Muscato of 10421 shares of Amedisys subject to Rule 16b-3 | 11/05/2024 |
6 | The Pennant Group, Inc. Q3 Earnings and Revenues Beat Estimates | 11/07/2024 |
7 | Market Today DOJ Challenges UnitedHealths Amedisys Deal, AbbVies Setback | 11/11/2024 |
8 | UnitedHealths 33B Deal With Hospice Provider Blocked By DOJ | 11/13/2024 |
9 | Disposition of 175 shares by Allyson Guidroz of Amedisys at 91.15 subject to Rule 16b-3 | 11/18/2024 |
10 | Principal Financial Group Inc. Sells 33,149 Shares of Amedisys, Inc. - MarketBeat | 11/20/2024 |
| Begin Period Cash Flow | 54.1 M |
Amedisys |
Amedisys Relative Risk vs. Return Landscape
If you would invest 9,790 in Amedisys on August 27, 2024 and sell it today you would lose (726.00) from holding Amedisys or give up 7.42% of portfolio value over 90 days. Amedisys is currently does not generate positive expected returns and assumes 0.7435% risk (volatility on return distribution) over the 90 days horizon. In different words, 6% of stocks are less volatile than Amedisys, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amedisys Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amedisys' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amedisys, and traders can use it to determine the average amount a Amedisys' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1581
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AMED |
Estimated Market Risk
| 0.74 actual daily | 6 94% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Amedisys is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amedisys by adding Amedisys to a well-diversified portfolio.
Amedisys Fundamentals Growth
Amedisys Stock prices reflect investors' perceptions of the future prospects and financial health of Amedisys, and Amedisys fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amedisys Stock performance.
| Return On Equity | 0.0721 | ||||
| Return On Asset | 0.0627 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 3.19 B | ||||
| Shares Outstanding | 32.75 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 1.28 X | ||||
| Revenue | 2.24 B | ||||
| Gross Profit | 453.98 M | ||||
| EBITDA | 216.91 M | ||||
| Net Income | (9.75 M) | ||||
| Cash And Equivalents | 17.96 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 487.21 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 35.05 X | ||||
| Cash Flow From Operations | 137.19 M | ||||
| Earnings Per Share | 2.52 X | ||||
| Market Capitalization | 2.97 B | ||||
| Total Asset | 2.06 B | ||||
| Retained Earnings | 747.92 M | ||||
| Working Capital | 23.21 M | ||||
| Current Asset | 175.26 M | ||||
| Current Liabilities | 175.19 M | ||||
About Amedisys Performance
By analyzing Amedisys' fundamental ratios, stakeholders can gain valuable insights into Amedisys' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Amedisys has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amedisys has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 6.57 | 6.30 | |
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | 0.10 | 0.10 | |
| Return On Equity | (0.01) | (0.01) |
Things to note about Amedisys performance evaluation
Checking the ongoing alerts about Amedisys for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amedisys help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amedisys generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 2.24 B. Net Loss for the year was (9.75 M) with profit before overhead, payroll, taxes, and interest of 453.98 M. | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Principal Financial Group Inc. Sells 33,149 Shares of Amedisys, Inc. - MarketBeat |
- Analyzing Amedisys' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amedisys' stock is overvalued or undervalued compared to its peers.
- Examining Amedisys' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amedisys' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amedisys' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amedisys' stock. These opinions can provide insight into Amedisys' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |